Literature DB >> 17913544

Pre-existing anti-Salmonella vector immunity prevents the development of protective antigen-specific CD8 T-cell frequencies against murine listeriosis.

Victòria E Sevil Domènech1, Klaus Panthel, Katrin M Meinel, Sebastian E Winter, Holger Rüssmann.   

Abstract

Our laboratory has focused its research on the use of the type III secretion system of Salmonella enterica serovar Typhimurium to translocate heterologous antigens directly into the cytosol of antigen-presenting cells. We have previously reported that the single oral immunization of mice with a recombinant Salmonella aroA/sptP mutant strain expressing the translocated Yersinia outer protein E fused to the immunodominant antigen p60 from Listeria monocytogenes in a type III-mediated fashion results in the efficient induction of p60-specific CD8 T cells and confers protection against a lethal Listeria challenge infection. In the present study, we determined whether pre-existing anti-Salmonella vector immunity influences the induction of p60-specific CD8 T cells and modulates protective immunity against listeriosis after oral vaccination with recombinant Salmonella. After single oral immunization, the Salmonella aroA/sptP double mutant strain was found to colonize spleens of mice for 21days. In contrast, the period of colonization was significantly shortened to 6days due to anti-Salmonella vector immunity after second oral immunization. The latter scenario led to the induction of low-level frequencies of antigen-specific CD8 T cells. Compared to the significantly higher numbers of p60-specific T lymphocytes elicited after single oral immunization, the low amount of Listeria-specific CD8 T cells did not confer protection against listeriosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913544     DOI: 10.1016/j.micinf.2007.07.010

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  8 in total

1.  Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.

Authors:  Birgit Korioth-Schmitz; Casey C Perley; Jaimie D Sixsmith; Eva M Click; Sunhee Lee; Norman L Letvin; Richard Frothingham
Journal:  Vaccine       Date:  2015-07-17       Impact factor: 3.641

2.  Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella enterica serovar typhimurium.

Authors:  Christina Berchtold; Klaus Panthel; Stefan Jellbauer; Brigitte Köhn; Elisabeth Roider; Miriam Partilla; Jürgen Heesemann; Stefan Endres; Carole Bourquin; Holger Rüssmann
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

3.  Influence of promoter, gene copy number, and preexisting immunity on humoral and cellular responses to a vectored antigen delivered by a Salmonella enterica vaccine.

Authors:  Manvendra Saxena; Peter J Coloe; Peter M Smooker
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

Review 4.  Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Authors:  Laurence M Wood; Yvonne Paterson
Journal:  Front Cell Infect Microbiol       Date:  2014-05-12       Impact factor: 5.293

5.  Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice.

Authors:  Essie Komla; Oscar B Torres; Rashmi Jalah; Agnieszka Sulima; Zoltan Beck; Carl R Alving; Arthur E Jacobson; Kenner C Rice; Gary R Matyas
Journal:  Vaccines (Basel)       Date:  2021-06-01

Review 6.  Pre-existing immunity against vaccine vectors--friend or foe?

Authors:  Manvendra Saxena; Thi Thu Hao Van; Fiona J Baird; Peter J Coloe; Peter M Smooker
Journal:  Microbiology       Date:  2012-11-22       Impact factor: 2.777

Review 7.  Live bacterial vaccine vectors: an overview.

Authors:  Adilson José da Silva; Teresa Cristina Zangirolami; Maria Teresa Marques Novo-Mansur; Roberto de Campos Giordano; Elizabeth Angélica Leme Martins
Journal:  Braz J Microbiol       Date:  2015-03-04       Impact factor: 2.476

Review 8.  Recombinant vectors as influenza vaccines.

Authors:  Sarah A Kopecky-Bromberg; Peter Palese
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.